You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萬孚生物(300482.SZ)上半年淨利潤預增20%-25%
格隆匯 07-12 20:39

格隆匯7月12日丨萬孚生物(300482.SZ)公佈,預計2021年上半年歸屬於上市公司股東的淨利潤53879.76萬元-56124.75萬元,同比增長20%-25%。

今年以來全球新冠疫情仍有反覆,經營環境依然存在不確定性但公司克服重重困難仍然實現了常規業務的高速增長和新冠業務的快速響應

報吿期內,國內市場已趨於穩定,各級醫院的診療量也基本恢復至疫情前水平公司順以病種和應用場景為業務驅動的行業趨勢對國內營銷事業部進行了組織化改革,通過員整合渠道複用帶動各業務條線的協同發展,推動化學發光分子病理等戰略新興平台的加速佈局和拓展。報吿期內國內銷售實現了同比快速增長

海外新冠產品的銷售提升了海外醫療專業機構對公司品牌的認可也促進了常規產品的渠道和終端的擴張。公司持續推進在海外重點國家“本地化經營”的策略,在團隊、渠道、售後等多個層面強化投入。報吿期內海外的常規業務實現了同比高速的增長。

在新冠業務上公司基於在過去數年間參與公共衞生系統建設的資源和經驗,對以德國為核心區域的新冠自測產品的市場需求做到了快速響應和迅速擴張。新冠業務總體呈現出穩定發展的態勢

報吿期內,歸屬於上市公司股東的非經常性損益金額為4600萬元左右,主要為政府補助、理財產品投資收益。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account